NI 0101

Drug Profile

NI 0101

Alternative Names: NI-0101

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovImmune SA
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 12 May 2017 Phase-II clinical trials in Rheumatoid arthritis in Hungary, Bulgaria (IV) (EudraCT2016-005017-45)
  • 05 Dec 2016 NovImmune and Genentech enter into an agreement for the exclusive option to license NI 0101, for the treatment of rheumatoid arthritis and other autoimmune diseases
  • 05 Dec 2016 NovImmune plans a phase II trial for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top